PRELUDE THERAPEUTICS INC Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax
PRELUDE THERAPEUTICS INC (PRLD) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax of $284.00 thousand as of 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Notes › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2024-02-15
- 2023-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $284.00K.
- 2023-09-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $11.00K.
- 2022-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $7.00K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2023-12-31 | $284.00K 10-K · filed 2024-02-15 |
| 2023-09-30 | $11.00K 10-Q · filed 2023-11-01 |
| 2022-12-31 | $7.00K 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |